Bristol-Myers Squibb Co. and Infinity Pharmaceuticals Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Infinity’s IPI-549 in patients with advanced urothelial cancer.
Last week’s issue of The Cancer Letter included an obituary that the entire staff at The Cancer Letter had been dreading for years: Abdallah Abou Zahr, an oncologist at Roger Maris Cancer Center in Fargo, ND, died Jan. 23 of a liposarcoma after a five-year battle with the disease.
